Rhodium-based metallodrugs for biological applications: current status and future perspectives
Source abstract
Abstract
Metal complexes represent a promising avenue in drug research and development, exemplified by metallodrugs including cisplatin, carboplatin, and oxaliplatin that have been clinically approved for the treatment of various solid tumors. However, most of the reported metallodrugs suffer from compromised therapeutic efficacy due to multidrug resistance (MDR) and severe systemic toxicity. Rhodium is another useful member of the platinum group metals in addition to the extensively explored platinum, whose complexes have attracted increasing attention in bioinorganic and medicinal chemistry not only for their low oxophilicity, broad functional-group tolerance, and superior catalytic performance, but also for their intriguing self-assembly behaviors and photophysical properties arising from the intermolecular metallophilic interactions. Together with the tremendous progresses made in the nanotechnology and biotechnology, targeted delivery of rhodium-based metallodrugs to lesion sites in either a passive or active means, or via a biomimetic strategy enables state-of-the-art approaches with great therapeutic efficiency. Nonetheless, there remains a critical lack of comprehensive reviews with a focus on rhodium complexes and their nanodrug derivatives. Here we systematically summarize the existing research on this hot subject of research, and provides a dynamic in-depth overview of the design and development of rhodium complexes and rhodium-containing nanomaterials across various medicine fields, including biomedical imaging, cancer therapy, antibacterial treatments, and anti-inflammatory applications. Critical evaluations are performed on the current challenges and future prospects of this rapidly developing field, for the purpose of promoting a thorough understanding of the latest advancements and further inspiring upcoming notable studies.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Radiopharmaceutical Chemistry and Applications · Nanomaterials for catalytic reactions · Chemical Reactions and Isotopes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Noble metals in medicine: latest advances10.1016/j.ccr.2014.08.002 ↗
2. Metallodrugs in cancer nanomedicine10.1039/D1CS00468A ↗
3. Platinum coordination compounds with potent anticancer activity10.1016/j.ccr.2017.11.014 ↗
4. The resurgence of platinum-based cancer chemotherapy10.1038/nrc2167 ↗
5. Metallodrugs in medicinal inorganic chemistry10.1021/cr400460s ↗
6. Stimuli-responsive metal complexes for biomedical applications10.1002/anie.202205900 ↗
7. Recent advances in the synthesis, stability, and activation of platinum (IV) anticancer prodrugs10.1016/j.ccr.2021.213991 ↗
8. Advancement of metal compounds as therapeutic and diagnostic metallodrugs: current frontiers and future perspectives10.1016/j.ccr.2021.214104 ↗
9. The rediscovery of platinum-based cancer therapy10.1038/s41568-020-00308-y ↗
10. Recent development of gold(I) and gold(III) complexes as therapeutic agents for cancer diseases10.1039/D1CS00933H ↗
11. 45Rh rhodium in medicine
12. Engineering precision nanoparticles for drug delivery10.1038/s41573-020-0090-8 ↗
13. Recent advances in biological activities of rhodium complexes: their applications in drug discovery research10.1016/j.ejmech.2021.113308 ↗
14. Rhodium complexes as therapeutic agents10.1039/C5DT04338G ↗
15. Rhodium at the chemistry-biology interface10.1039/C8DT03032D ↗
16. Rhodium and its compounds as potential agents in cancer treatment10.1016/S1040-8428(01)00222-0 ↗
17. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
18. Versatile delivery systems for non-platinum metal-based anticancer therapeutic agents10.1016/j.ccr.2021.213975 ↗
19. Antitumour action of planar, organometallic rhodium(I) complexes10.1016/0009-2797(74)90020-9 ↗
20. A potential rhodium cancer therapy: studies of a cytotoxic organorhodium(I) complex that binds DNA10.1016/j.bmcl.2013.03.016 ↗
21. In vitro evaluation of rhodium and osmium RAPTA analogues: the case for organometallic anticancer drugs not based on ruthenium10.1021/om060394o ↗
22. Metal N-heterocyclic carbene complexes as potential antitumor metallodrugs10.1039/C2CS35314H ↗
23. A chemical-biological evaluation of rhodium(I) N-heterocyclic carbene complexes as prospective anticancer drugs10.1002/chem.201302819 ↗
24. Rhodium(i) N-heterocyclic carbene complexes: synthesis and cytotoxic properties10.1039/D1NJ00144B ↗
25. Rhodium(I) N-heterocyclic carbene bioorganometallics as in vitro antiproliferative agents with distinct effects on cellular signaling10.1021/acs.jmedchem.5b01159 ↗
26. A new rhodium(I) NHC complex inhibits TrxR: in vitro cytotoxicity and in vivo hepatocellular carcinoma suppression10.1016/j.ejmech.2019.111721 ↗
27. A combined spectroscopic and protein crystallography study reveals protein interactions of Rh(I)(NHC) complexes at the molecular level10.1021/acs.inorgchem.0c02438 ↗
28. Luminescent and photofunctional transition metal complexes: from molecular design to diagnostic and therapeutic applications10.1021/jacs.2c03437 ↗
29. Fluorescent organometallic rhodium(I) and ruthenium(II) metallodrugs with 4-ethylthio-1,8-naphthalimide ligands: antiproliferative effects, cellular uptake and DNA-interaction10.1016/j.ejmech.2018.06.056 ↗
30. Unveiling luminescent Ir(I) and Rh(I) N-heterocyclic carbene complexes: structure, photophysical specifics, and cellular localization in the endoplasmic reticulum10.1002/chem.202100375 ↗
31. Studies of rhodium (II) carboxylates as potential antitumor agents10.3181/00379727-145-37996 ↗
32. Interaction of rhodium (II) carboxylates with molecules of biologic
33. The interaction of rhodium (II) carboxylates with enzymes
34. Mechanism of action of tetra-μ-carboxylatodirhodium (II) in L1210 tumor suspension culture
35. Bioactive iridium and rhodium complexes as therapeutic agents10.1016/j.ccr.2013.01.034 ↗
36. Effects of human serun albumin in some biological properties of rhodium (II) complexes10.1590/S0103-50532000000500003 ↗
37. Dinuclear Rh(II) complexes with one polypyridyl ligand, structure, properties and antitumor activity10.1016/j.ica.2010.03.061 ↗
38. Rhodium (II) complex with 2-benzoylpyridine, a novel potential chemotherapeutic drug, induces cell cycle arrest and apoptosis in HepG2 cells10.1007/s10534-017-0056-4 ↗
39. Rhodium(II) proximity-labeling identifies a novel target site on STAT3 for inhibitors with potent anti-leukemia activity10.1002/anie.201506889 ↗
40. Assessing the intracellular fate of rhodium(ii) complexes10.1039/C6CC05192H ↗
41. Transition metal complexes as photosensitizers for integrated cancer theranostic applications10.1016/j.ccr.2020.213355 ↗
42. Metalloimmunotherapy with rhodium and ruthenium complexes: targeting tumor-associated macrophages10.1002/chem.202104430 ↗
43. Interaction of rhodium (III) with DNA10.1016/0005-2787(79)90071-6 ↗
44. Rhodium (III) complexes with polypyridyls and pyrazole and their antitumor activity10.1016/S0020-1693(02)00776-4 ↗
45. Phototoxicity against tumor cells and sindbis virus by an octahedral rhodium bisbipyridyl complex and evidence for the genome as a target in viral photoinactivation10.1021/ic0498586 ↗
46. Enhancing bioactivity of N,N,N-chelating rhodium(III) complexes with ionic liquids: toward targeted cancer therapy10.1021/acs.jmedchem.4c01220 ↗
47. DNA mismatch-specific targeting and hypersensitivity of mismatch-repair-deficient cells to bulky rhodium(III) intercalators, P. Nati10.1073/pnas.0607576103 ↗
48. Rhodium complexes targeting DNA mismatches as a basis for new therapeutics in cancers deficient in mismatch repair10.1021/acs.biochem.1c00302 ↗
49. A family of rhodium complexes with selective toxicity toward mismatch repair-deficient cancers10.1021/jacs.8b02271 ↗
50. Rhodium metalloinsertor binding generates a lesion with selective cytotoxicity for mismatch repair-deficient cells, P. Nati10.1073/pnas.1706665114 ↗
51. In vivo anticancer activity of a rhodium metalloinsertor in the HCT116 xenograft tumor model, P. Nati10.1073/pnas.2006569117 ↗
52. Inhibition of Janus kinase 2 by cyclometalated rhodium complexes
53. Antagonizing STAT3 dimerization with a rhodium(III) complex10.1002/anie.201404686 ↗
54. Synthesis, structure, DNA/protein binding, and cytotoxic activity of a rhodium (III) complex with 2, 6-bis (2-benzimidazolyl) pyridine10.1016/j.ejmech.2016.11.005 ↗
55. A rhodium(III)-Based inhibitor of lysine-specific histone demethylase 1 as an epigenetic modulator in prostate cancer cells10.1021/acs.jmedchem.7b00133 ↗
56. Selective inhibition of lysine-specific demethylase 5A (KDM5A) using a rhodium(III) complex for triple-negative breast cancer therapy10.1002/anie.201807305 ↗
57. Identification of a rhodium(iii) complex as a Wee1 inhibitor against TP53-mutated triple-negative breast cancer cells
58. A multitargeted approach: organorhodium anticancer agent based on vorinostat as a potent histone deacetylase inhibitor10.1002/anie.202005758 ↗
59. Ruthenium porphyrin compounds for photodynamic therapy of cancer10.1021/jm701382p ↗
60. Two-photon, red light uncaging of alkyl radicals from organorhodium(iii) phthalocyanine complexes10.1039/D2CC03672J ↗
61. Developing a rhodium(III) complex to reprogram the tumor immune and metabolic microenvironments: overcoming multidrug resistance and metastasis in non-small cell lung cancer10.1021/acs.jmedchem.4c01133 ↗
62. Rhodium(III) complex noncanonically potentiates antitumor immune responses by inhibiting Wnt/β-catenin signaling10.1021/acs.jmedchem.4c00583 ↗
63. Activation of the cGAS-STING pathway by a mitochondrial DNA-targeted emissive rhodium(iii) metallointercalator10.1039/D3SC01737K ↗
64. Recent advances in metal-based nanomaterials for malignant bone tumor therapy10.1016/j.ejmech.2025.117427 ↗
65. Antitumor effect and toxicity of free rhodium (II) citrate and rhodium (II) citrate-loaded maghemite nanoparticles in mice bearing breast cancer10.1186/1477-3155-11-4 ↗
66. Exploring cellular uptake of iron oxide nanoparticles associated with rhodium citrate in breast cancer cells10.2147/IJN.S141582 ↗
67. Morphology-controlled synthesis of rhodium nanoparticles for cancer phototherapy10.1021/acsnano.8b02698 ↗
68. Ultrasmall rhodium nanozyme with RONS scavenging and photothermal activities for anti-inflammation and antitumor theranostics of colon diseases10.1021/acs.nanolett.9b05035 ↗
69. Rhodium nanoparticles as a novel photosensitizing agent in photodynamic therapy against cancer10.1002/chem.202001112 ↗
70. Integration of transcriptomics and metabolomics to reveal the molecular mechanisms underlying rhodium nanoparticles-based photodynamic cancer therapy10.3390/pharmaceutics13101629 ↗
71. Catalytic rhodium (Rh)-based (mesoporous polydopamine) MPDA nanoparticles with enhanced phototherapeutic efficiency for overcoming tumor hypoxia10.1039/D0BM00625D ↗
72. Synergistic therapeutic antitumor effect of PD-1 blockade cellular vesicles in combination with Iguratimod and Rhodium nanoparticles10.1016/j.jcis.2023.06.030 ↗
73. Hypoxic control of metastasis10.1126/science.aaf4405 ↗
74. Chemical design and synthesis of functionalized probes for imaging and treating tumor hypoxia10.1021/acs.chemrev.6b00525 ↗
75. Multifunctional albumin–MnO2 nanoparticles modulate solid tumor microenvironment by attenuating hypoxia, acidosis, vascular endothelial growth factor and enhance radiation response10.1021/nn405773r ↗
76. A porous Au@Rh bimetallic core-shell nanostructure as an H2O2 -driven oxygenerator to alleviate tumor hypoxia for simultaneous bimodal imaging and enhanced photodynamic therapy
77. Metal–organic frameworks as potential drug carriers10.1016/j.cbpa.2009.12.012 ↗
78. The development of phosphorescent probes for in vitro and in vivo bioimaging10.1039/D0BM00819B ↗
79. Prospective feasibilities and strategies of MOFs on the treatment of oropharyngeal carcinoma
80. Prospects, advances and biological applications of MOF-based platform for the treatment of lung cancer10.1039/D4BM00488D ↗
81. ATP-responsive near-infrared fluorescence MOF nanoprobe for the controlled release of anticancer drug10.1007/s00604-021-04953-4 ↗
82. The novel use of Rh (I) complexes with naphthyridine ligands and poly (oxyethylene) as antitumorals10.1097/00001813-199601000-00010 ↗
83. Encapsulation and release of rhodium (II) citrate and its association complex with hydroxypropyl‐β‐cyclodextrin from biodegradable polymer microspheres10.1021/js9804314 ↗
84. Light-emitting self-assembled materials based on d8 and d10 transition metal complexes10.1021/acs.chemrev.5b00074 ↗
85. In situ assembly of platinum(II)-Metallopeptide nanostructures disrupts energy homeostasis and cellular metabolism10.1021/jacs.2c03215 ↗
86. Intracellular dynamic assembly of deep‐red emitting supramolecular nanostructures based on the Pt···Pt metallophilic interaction10.1002/adma.202008613 ↗
87. The self-assembly of a cyclometalated palladium photosensitizer into protein-stabilized nanorods triggers drug uptake in vitro and in vivo10.1021/jacs.0c01369 ↗
88. In vivo metallophilic self-assembly of a light-activated anticancer drug10.1038/s41557-023-01199-w ↗
89. Phosphorescent NIR emitters for biomedicine: applications, advances and challenges10.1039/D1DT03077A ↗
90. Synthesis, supramolecular aggregation, and NIR-II phosphorescence of isocyanorhodium(i) zwitterions10.1039/D3SC03508E ↗
91. Efficient and stable NIR‐II phosphorescence of metallophilic molecular oligomers for in vivo single‐cell tracking and time‐resolved imaging
92. Rhodium(I) complex-based polymeric nanomicelles in water exhibiting coexistent near-infrared phosphorescence imaging and anticancer activity in vivo10.1021/jacs.9b11013 ↗
93. Brief survey on organometalated antibacterial drugs and metal-based materials with antibacterial activity10.1039/D0CB00218F ↗
94. Bioinorganic antimicrobial strategies in the resistance era10.1016/j.ccr.2017.05.005 ↗
95. Inhibition of bacterial growth and nucleic acids synthesis by planar complexes of rhodium (I)10.1016/0014-5793(74)81093-8 ↗
96. SYNTHESIS, characterization and ANTI-BACTERIAL studies of some LOW-VALENT organometallic derivatives of Pd (0), Pt (0), Rh (I) and Ir (I) with 2-THIOBARBITURIC acid, Rasayan
97. Properties and biological activity of [Rh(COD)(N–N)]BF4 and [IrCl2(COD)(N–N)]BF4 polypyridyl complexes10.1016/j.ica.2013.02.002 ↗
98. Synthesis, spectroscopic, structural, DFT and antibacterial studies of cyclometalated rhodium(III) complex based on morpholinedithiocarbamate ligand10.1016/j.inoche.2021.108707 ↗
99. Antibacterial, DFT and molecular docking studies of Rh(III) complexes of Coumarinyl‐Thiosemicarbazone nuclei based ligands
100. Experimental and DFT studies of sulfadiazine 'piano-stool' Ru(ii) and Rh(iii) complexes10.1039/D0RA01085E ↗